Sign in

CIK 0000072444

  • Accelerated filer
  • Smaller reporting company

Vaxart, Inc.

Sign in to watch
Ticker
VXRT
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
591212264
Phone
+1 650-550-3500
Business address
310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
Former names
Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2009-06-29 KNOTT DAVID M 10% owner Sale −55,500 $2.52 $140K 1,140,000
2009-06-29 KNOTT DAVID M 10% owner Sale −53,800 $2.52 $136K 1,784,153
2009-06-29 KNOTT DAVID M 10% owner Sale −300 $2.52 $756 70,100
2009-05-29 FAHIM RAAFAT E F President, CEO and CFO Other acquisition +5,404.28 $2.41 $13K 278,414.66
2009-05-22 SUDOVAR STEPHEN Director Grant or award · Stock Option (right to buy) +20,000 20,000
2009-05-22 LYNCH TIMOTHY P Director Grant or award · Stock Option (right to buy) +20,000 20,000
2009-05-22 JENCKES LINDA Director Grant or award · Stock Option (right to buy) +20,000 20,000
2009-05-22 HARVEY RICHARD A JR Director Grant or award · Stock Option (right to buy) +20,000 20,000
2009-05-22 DAVIS PETER B Director Grant or award · Stock Option (right to buy) +20,000 20,000
2009-05-22 COX GEOFFREY F Director Grant or award · Stock Option (right to buy) +40,000 40,000
2009-05-22 CASTALDI DAVID L Director Grant or award · Stock Option (right to buy) +20,000 20,000
2009-05-22 Aryeh Jason Director Grant or award · Stock Option (right to buy) +20,000 20,000
2009-04-01 Kalnik Matthew W. SVP Strategic Plan. & Bus. Ops Grant or award +18,000 45,692.82
2009-04-01 Kalnik Matthew W. SVP Strategic Plan. & Bus. Ops Grant or award · Stock Option (Right to Buy) +45,000 45,000
2009-04-01 Kessler Paul D. SVP Clinical, Med. & Reg.; CMO Grant or award +30,000 101,240
2009-04-01 Kessler Paul D. SVP Clinical, Med. & Reg.; CMO Grant or award · Stock Option (Right to Buy) +90,000 90,000
2009-04-01 FAHIM RAAFAT E F President, CEO and CFO Grant or award +45,000 270,063.53
2009-04-01 FAHIM RAAFAT E F President, CEO and CFO Grant or award · Stock Option (Right to Buy) +115,000 115,000
2009-01-12 KNOTT DAVID M 10% owner Purchase +58,500 $3.84 $225K 139,800
2008-05-07 SUDOVAR STEPHEN Director Grant or award · Stock Option (right to buy) +20,000 20,000

Page 35 of 42 · 830 trades